Czechia· CZ-0194521
GIOTRIF
A afatinib product containing afatinib dimaleate, registered in Czechia by Boehringer Ingelheim International GmbH, Ingelheim am Rhein. The same ATC class is registered in 12 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Afatinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EB03 (afatinib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Afatinib · ATC L01EB03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of afatinib costs, country by country.
Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Afatinib · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- CH Switzerland$199.66
The record
At a glance
SÚKL (Czech Republic)- Active substance
- AFATINIB DIMALEATE
- Manufacturer
- Boehringer Ingelheim International GmbH, Ingelheim am Rhein
- Country
- Czechia (CZ)
- ATC code
- L01EB03
- ATC class
- Afatinib
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
170 interactions on record for afatinib.
Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Afatinib · interactions on record
170 records
- 10 severe
- 158 moderate
- 2 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- PexidartinibL01EX15severe
- Aminolevulinic acidL01XD04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Afatinib in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumGiotrif 30 mgBoehringer Ingelheim International
- FinlandGIOTRIFBoehringer Ingelheim International GmbH
- United StatesAfatinibCamber Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Malta · Afatinib
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3e576c27-8758-4548-958d-a9d34d477654 GET /v1/drugs/3e576c27-8758-4548-958d-a9d34d477654?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "30MG",
"pack_size": "7X1",
"substance": "AFATINIB DIMALEATE",
"cz_kod_sukl": "0194521",
"product_type": "CH",
"substance_codes": "20247",
"registration_state": "R",
"registration_number": "EU/1/13/879/004"
}See everything about afatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.